250 experts came together at Swiss TPH to discuss strategies to improve access to healthcare in LMICs. From left: Pierre Morgon (MRGN Advisors), Lutz Hegemann (Novartis), Honorati Masanja (Ifakara Health Institute) and Jutta Reinhard-Rupp (Merck). (Photo: Swiss TPH / Joachim Pelikan)
250 experts came together at Swiss TPH to discuss strategies to improve access to healthcare in LMICs. From left: Pierre Morgon (MRGN Advisors), Lutz Hegemann (Novartis), Honorati Masanja (Ifakara Health Institute) and Jutta Reinhard-Rupp (Merck). (Photo: Swiss TPH / Joachim Pelikan) Access to drugs, diagnostics and vaccines remains a challenge in many in lowand middle-income countries. Today, 8 February 2024, Swiss TPH hosted a symposium bringing together 350 experts and key players from academia, the pharmaceutical industry, politics and product development partnerships to assess current strategies and foster synergies in research, drug development and medicines' implementation. There are manifold challenges which can hinder access to medicines. They range all the way from limited funding for research on neglected diseases, complexity in drug development in resource-limited settings, all the way to barriers when integrating new tools and strategies in health systems. Today, 350 national and international experts, researchers and policy-makers came together physically and virtually at Swiss TPH to discuss ways to promote global health and improve access to medicines in lowand middle-income countries (LMICs).
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
